Granted Patent
B2
US 12,559,751 · App. 18/932,105 · Granted Feb 24, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.
Claims (4)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 2.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 12.
4 . The composition of claim 3 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072083/0016 →
Continuity (2)
Division
18517808
· Nov 22, 2023
References Cited (42)
CA 2721333A1
· 2009
[cited by applicant]
CN 108998451A
· 2018
[cited by applicant]
GenBank IL-1b gene Sequence Nov. 2023 version (Year: 2023).
[cited by examiner]
Fiona T van den Berg, et al., Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by examiner]
Denzler R et al., Mol Cell. Nov. 3, 2016;64(3):565-579 (Year: 2016).
[cited by examiner]
O'Brien, et al., Aug. 3, 2018, Front Endocrinol (Lausanne), 9:402, p. 1-12; Fig. 1; p. 2, “Biogenesis of miRNAs” (Year: 2018).
[cited by examiner]
Gorski, S., Vogel, J. & Doudna, J., Nat Rev Mol Cell Biol 18, 215-228 (2017) (Year: 2017).
[cited by examiner]
GenBank IL-1b mRNA Sequence Nov. 2023 version (Year: 2023).
[cited by examiner]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com. Accessed Dec. 23, 2024) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (Year: 2010).
[cited by examiner]
Tritschler (et al. 2019. Concepts and limitations for learning developmental trajectories from single cell genomics. Development 146: dev170506) (Year: 2019).
[cited by examiner]
Zhang et al. “Cytokines, inflammation, and pain.” International anesthesiology clinics 45.2 (2007): 27-37.
[cited by applicant]
WIPO translation of CN108998451 (2018).
[cited by applicant]
Asirvatham et al. “miRNA regulation of cytokine genes.” Cytokine 45.2 (2009): 58-69.
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
Shang et al. “microRNAs in action: biogenesis, function and regulation.” Nature Reviews Genetics 24.12 (2023): 816-833.
[cited by applicant]
Agarwal et al. “Predicting effective microRNA target sites in mammalian mRNAs.” elife 4 (2015): e05005.
[cited by applicant]
Fayyad-Kazan et al. “Downregulation of microRNA-24 and-181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes.” Human immunology 75.7 (2014): 677-685.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
NCBI Search results for SEQ ID No. 5 2024.
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019;18(5):358-378. (Year: 2019).
[cited by applicant]
Momin et al., 2021, Cells, 10, 3097, p. 1-21 (Year: 2021).
[cited by applicant]
“The Risks of miRNA Therapeutics: In a Drug Target Perspective” (Zhang et al.—2021).
[cited by applicant]
GenBank IL-1b gene Sequence (2023).
[cited by applicant]
[cited by applicant]
Lam et al. “siRNA versus miRNA as therapeutics for gene silencing.” Molecular therapy Nucleic acids 4 (2015).
[cited by applicant]
Ying et al. “The microRNA (miRNA): overview of the RNA genes that modulate gene function.” Molecular biotechnology 38 (2008): 257-268.
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]